Key points are not available for this paper at this time.
You have accessJournal of UrologySexual Function/Dysfunction: Basic Research Prkg1), an effector protein of the NO pathway was highly expressed in ASMCs compared to PDGFRα+ cells. Evaluation of the expression of adrenergic receptors α1-AR (Adra1a) and α2-AR (Adra2a) revealed that the predominant receptor was α1-AR, with ASMCs expressing Adra1a more robustly than in PDGFRα+ cells. CONCLUSIONS: This data suggests that inhibitory and excitatory neurotransmitters released in the CC may mediate their effects through PDGFRα+ cells and ASMCs. An important area for future study is to further characterize these cell types as they may represent a therapeutic target for the treatment of erectile dysfunction. Source of Funding: AUA Research Scholar Award to KIH, NIH DK129528 to CAC, NIH P20GM130459 for imaging and molecular cores © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1088 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Karen I. Hannigan More articles by this author Emily B. Fox More articles by this author Caroline A. Cobine More articles by this author Expand All Advertisement PDF downloadLoading ...
Hannigan et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: